Tonix Pharmaceuticals Holding Corp. SEC filings TNXP
Tonix Pharmaceuticals Holding Corp. has 1,000 filings in SEC EDGAR's recent list, going back to May 2, 2017. Its latest annual report, Form ARS, was filed on Mar 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Mar 30, 2026 | May 7, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 20, 2026 | May 7, 2026 |
| DEF 14A | Proxy statement | Mar 31, 2025 | May 8, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2025 | May 8, 2025 |
| DEF 14A | Proxy statement | Sep 23, 2024 | Oct 30, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 13, 2024 | Oct 30, 2024 |
| DEF 14A | Proxy statement | Apr 15, 2024 | May 22, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2024 | May 22, 2024 |
| DEF 14A | Proxy statement | Jan 8, 2024 | Feb 15, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 29, 2023 | Feb 1, 2024 |
| DEF 14A | Proxy statement | Dec 26, 2023 | Jan 25, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 20, 2023 | Oct 20, 2023 |
| DEF 14A | Proxy statement | Mar 17, 2023 | May 5, 2023 |
| DEF 14A | Proxy statement | Nov 7, 2022 | Dec 13, 2022 |
| PRE 14A | Preliminary proxy statement | Oct 28, 2022 | Dec 13, 2022 |
| DEF 14A | Proxy statement | Jul 5, 2022 | Aug 5, 2022 |
| PRE 14A | Preliminary proxy statement | Jun 24, 2022 | Jun 24, 2022 |
| DEF 14A | Proxy statement | Mar 18, 2022 | May 6, 2022 |
| DEF 14A | Proxy statement | Dec 23, 2021 | Feb 10, 2022 |
| PRE 14A | Preliminary proxy statement | Dec 10, 2021 | Dec 10, 2021 |
| DEF 14A | Proxy statement | Mar 31, 2021 | May 7, 2021 |
| DEF 14A | Proxy statement | Feb 11, 2021 | Mar 26, 2021 |
| PRE 14A | Preliminary proxy statement | Jan 29, 2021 | Mar 26, 2021 |
| DEFA14A | Additional proxy material | Jul 21, 2020 | — |
| DEFA14A | Additional proxy material | Jul 21, 2020 | — |
| DEFA14A | Additional proxy material | Jun 29, 2020 | — |
| DEF 14A | Proxy statement | May 15, 2020 | Jun 26, 2020 |
| PRE 14A | Preliminary proxy statement | May 5, 2020 | Jun 26, 2020 |
| DEF 14A | Proxy statement | Mar 30, 2020 | May 1, 2020 |
| DEF 14A | Proxy statement | Dec 13, 2019 | Jan 16, 2020 |
| PRE 14A | Preliminary proxy statement | Dec 2, 2019 | Jan 16, 2020 |
| DEF 14A | Proxy statement | Mar 18, 2019 | May 3, 2019 |
| DEFA14A | Additional proxy material | May 29, 2018 | — |
| DEF 14A | Proxy statement | Apr 19, 2018 | Jun 8, 2018 |
| DEF 14A | Proxy statement | May 2, 2017 | Jun 16, 2017 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1430306
- Former names
- TAMANDARE EXPLORATIONS INC. (until Oct 17, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.